DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries. Despite a ...

Let’s dig into the relative performance of DexCom (NASDAQ:DXCM) and its peers as we unravel the now-completed Q4 patient ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...

DexCom has barely scratched the surface of its niche in the diabetes market. As a result of industry challenges, the stock's valuation has now come down. But from here, the stock looks well-positioned ...

If you are wondering whether DexCom's current share price lines up with its underlying worth, or if the market is mispricing the stock, this article walks through that question step by step. DexCom ...

DexCom (DXCM) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

SHANGHAI, CHINA - JANUARY 25, 2022 - A 3M logo display of air-condensed thermal materials in a shopping mall in Shanghai, China, January 25, 2022. (Photo credit should read Wang Gang / Costfoto/Future ...

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

Over the past five years, diabetes-focused medical device specialist DexCom (NASDAQ: DXCM) has made meaningful progress on several fronts. The company launched new products in the continuous glucose ...